Biased signaling at class B GPCRs opens door to safer, more effective peptide drug design
Class B GPCRs (15 peptide hormone receptors including GLP-1R, CGRP-R, and PACAP receptors) can be targeted with biased agonists/antagonists that activate specific signaling pathways, enabling drugs with enhanced efficacy and reduced side effects.
Quick Facts
What This Study Found
Class B GPCRs: 15 peptide hormone receptors. Recent approvals: migraine (CGRP), diabetes (GLP-1), obesity. Biased signaling enables pathway-selective drugs. Designer drugs: enhanced efficacy, reduced side effects. Applicable to GLP-1R, CGRP-R, PACAP receptors, and others.
Key Numbers
How They Did This
Narrative review of biased signaling pharmacology at class B GPCRs, covering approved therapeutics and drug development.
Why This Research Matters
Understanding that GLP-1 and CGRP receptors can be activated in pathway-selective ways opens doors to next-generation drugs that maximize therapeutic effects while minimizing side effects.
The Bigger Picture
Biased signaling is the frontier of peptide drug design. Rather than activating all downstream pathways (causing side effects), future drugs will activate only the beneficial ones—a precision pharmacology approach.
What This Study Doesn't Tell Us
Narrative review. Biased signaling measurement is complex. Translation from in vitro bias to clinical outcomes is uncertain. Few biased drugs have reached clinical testing.
Questions This Raises
- ?Which signaling pathway is most important for GLP-1 weight loss vs GI side effects?
- ?Can biased GLP-1 agonists reduce nausea while maintaining efficacy?
- ?Will CGRP receptor biased antagonists provide migraine relief without immune effects?
Trust & Context
- Key Stat:
- Pathway-selective drug design Biased signaling at class B GPCRs enables "designer" peptide drugs that activate therapeutic pathways while avoiding side-effect-causing ones—the future of GLP-1 and CGRP therapeutics
- Evidence Grade:
- Narrative review of established pharmacological principles with emerging applications.
- Study Age:
- Published in 2025.
- Original Title:
- Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics.
- Published In:
- Pharmacology & therapeutics, 270, 108846 (2025)
- Authors:
- Tasma, Zoe(4), Garelja, Michael L, Jamaluddin, Aqfan, Alexander, Tyla I, Rees, Tayla A
- Database ID:
- RPEP-13779
Evidence Hierarchy
Frequently Asked Questions
What is biased signaling?
When a drug activates a receptor, it can trigger multiple downstream pathways. Biased signaling means designing drugs that activate only the beneficial pathways while avoiding the ones that cause side effects. For GLP-1 drugs, this could mean weight loss without nausea.
Could this make GLP-1 drugs better?
Yes. Current GLP-1 drugs activate all signaling pathways at the receptor, including those causing nausea and vomiting. Biased agonists could be designed to activate the appetite-suppressing pathway while avoiding the nausea pathway—potentially transforming tolerability.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13779APA
Tasma, Zoe; Garelja, Michael L; Jamaluddin, Aqfan; Alexander, Tyla I; Rees, Tayla A. (2025). Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics.. Pharmacology & therapeutics, 270, 108846. https://doi.org/10.1016/j.pharmthera.2025.108846
MLA
Tasma, Zoe, et al. "Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics.." Pharmacology & therapeutics, 2025. https://doi.org/10.1016/j.pharmthera.2025.108846
RethinkPeptides
RethinkPeptides Research Database. "Where are we now? Biased signalling of Class B G protein-cou..." RPEP-13779. Retrieved from https://rethinkpeptides.com/research/tasma-2025-where-are-we-now
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.